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Background: Previous epidemiologic studies have demonstrated an association between uric acid and
hypertension. Our objective was to conduct a prospective cohort study with a nested randomised controlled trial
(RCT in cohort) that aims to identify the association of hyperuricemia with the development of hypertension and to
examine the efficacy of dietary intervention in lowering uric acid level and prevention of hypertension.
Methods/Design: Participants were considered eligible to enrol for this cohort study if they were not diagnosed with
hypertension until their last routine health examination. The characteristics of the eligible participants were analyzed.
After enrolment, participants with prehypertension and hyperuricemia simultaneously were randomly distributed to
either the intervention group or the control group. An education package of dietary intervention for lowering uric acid
was delivered to the intervention group. The primary evaluation criterion was the first manifestation of hypertension.
Discussion: Based on the results of their health examination in 2010, 19, 724 subjects met the inclusion criteria and
this source population guaranteed the required minimum sample size for this study. The baseline characteristics of the
study cohort showed that hyperuricemia was associated with prehypertension, and was independent of age, body
mass index (BMI), and abdominal obesity in females; however, in males it was contrary.
The impact of lowering uric acid on the prevention of hypertension is still inconclusive. This RCT in cohort study
provides important data on the prevention of hypertension, especially in patients with a high risk for hypertension
development. Results are expected to be available in 2015.
Trial registration: The study is registered with the Chinese Clinical Trial Registry (ChiCTR-TRC-12002925).
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Previous epidemiologic studies have demonstrated an as-
sociation between uric acid and hypertension [1]. Experi-
mental evidence supports a causal role of serum uric
acid in hypertension development [2]. Higher serum uric
acid levels were also positively associated with prehyper-
tension when hypertension prevention efforts may be
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reproduction in any medium, provided the or(BMI), diabetes, and other confounders [3]. In addition,
a significant decrease in the systolic blood pressure was
observed in patients with hyperuricemia and hyperten-
sion after a reduction in the intake of food sources
containing purines [4]. Based on the existing body of
evidence, it appears that hyperuricemia patients with
high normal blood pressure would benefit from low-
ering uric acid dietary intervention for the prevention
or postponement of the development of hypertension.
There seems to be sufficient evidence to warrant fur-
ther studies to determine whether lowering uric acid
levels would be of clinical benefit in the prevention oftd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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spective cohort study with a nested randomised con-
trolled trial (RCT in cohort) that aims to examine the




The study is a prospective cohort study with a nested
randomised controlled trial. The objectives are to iden-
tify the association of hyperuricemia with the develop-
ment of hypertension and to examine the efficacy of
dietary intervention in lowering uric acid level and its
impact on prevention of hypertension. Participants were
randomly enrolled in this study cohort when they had
their yearly routine health examinations in the depart-
ment of Health Examination at the General Hospital in
Tianjin, China in 2010. Participants who had hyperten-
sion were excluded. 19, 724 subjects met the inclusion
criteria. The study cohorts include the following four
groups: normal tension and no hyperuricemia (NN), pre-
hypertension and no hyperuricemia (PN), normal ten-
sion and hyperuricemia (NH), NH)and prehypertension
and hyperuricemia (PH). After enrolment, participants
who had prehypertension and hyperuricemia were ran-
domised either to the intervention group (PHI) or the
control group (PHC). Participants were randomized by a
computer-generated number, which was concealed in se-
quentially numbered, sealed, and opaque envelopes, and
kept by a trained nutritionist who delivered the interven-
tion. Ethical approval was obtained from the ethical
committee of the Tianjin Medical University (Additional
file 1). Signed informed consent was obtained from all
the participants (Additional file 2).
Investigational plan
Table 1 summarizes the investigation plan. The cohort
will be followed for at least for 5 years. Baseline demo-
graphic information including age, gender, social history
and habits, and family history was collected after enrol-
ment. Subjects were asked to have their annually sched-
uled health examination and finish a questionnaire on
lifestyle factors and medical history at each scheduledTable 1 Documentation and investigation plan
Documentation or investigation Base
Consent form W
Questionnaire-demographic information W
Questionnaire-lifestyle factors and medical history W
Blood pressure W
Blood screening-Uric acid W
Laboratory values: Total cholesterol, LDL-C, HDL-C, TG, Blood glucose W
LDL-C: Low-density lipoprotein concentrations, HDL-C: High-density lipoprotein conhealth examination. A question was designed to investi-
gate average salt intake of family members and a supple-
mental question was used to identify if the participant
favored more or less salty food than other family mem-
bers. The patients were asked if they were diagnosed
with hypertension in the previous period before the
scheduled health examination and the time was docu-
mented. Subjects in RCT for both the intervention and
control groups were asked to attend three additional
scheduled visits at 3 months, 6 months, and 18 months
after the first study health examination.
Description of intervention in RCT
Participants were asked to answer questionnaires about
their dietary habits and lifestyle. After evaluating the
participants’ dietary habits and lifestyle, a trained nutri-
tionist will make tailored recommendations for each par-
ticipant. An information letter that included the tailored
recommendations was sent to the subjects after the face-
to-face health-related advisory service. Generally, three
modules were included: risk of hyperuricemia, dietary
recommendations with lists of restricted and recom-
mended food according to the subject’s recollection, and
lifestyle modification recommendations.
Measurements and definitions
A trained nurse measured blood pressure under controlled
conditions by using a portable digital blood pressure
monitor (Omron HEM-705CP). Blood pressure was mea-
sured three times in succession with the subject seated,
with the left arm at heart level, and cuff adjusted for arm
circumference. For each subject, the mean of the second
and third readings was used for the analysis of systolic
blood pressure (SBP) and diastolic blood pressure (DBP)
data. Prehypertension is defined as the SBP between 120
and 139 or DBP between 80 and 89 mm Hg without using
anti-hypertension medication according to the Seventh
Report of the Joint national Committee on Prevention,
Detection, Evaluation, and Treatment of High Blood
Pressure guidelines. Hypertension is defined as SBP > 140
or DBP > 90 mm Hg or using anti-hypertensive medication.
Body mass index (BMI) is used as an index of relative
weight. Waist circumference (WC) is used as a measureline 3 Mo 6 Mo 1 Yr 18 Mo 2 Yr 3 Yr 4 Yr 5 Yr
R R W R W W W W
R R W R W W W W
R R W R W W W W
W W W W W
centrations, TG: Triglycerides.
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circumference are based on the mean of two measure-
ments. Overweight is defined as BMI ≥ 24 kg/m2, and
obesity as BMI of ≥ 28 kg/m2 while abdominal obesity is
defined as WC > 90 cm in male and 85 cm in female.
Venous blood samples were obtained after an overnight
fast and they were subjected to centrifugation at 3000
rpm for 30 minutes at 4°C. Serum uric acid, triglycerides
(TG), high-density lipoprotein (HDL) and low-density
lipoprotein (LDL) concentrations, and fasting glucose
were determined enzymatically by an auto-analyzer
(Hitachi Model 7170 analyzer, Hitachi, Tokyo, Japan).
Hyperuricemia is defined as a serum uric acid value
above 6.0 mg/dL for females or above 7.0 mg/dL for
males. Renal function was assessed by testing creatine,
creatinine-urine, creatine clearance, and BUN.
Estimation of minimum sample size
For the consideration of the RCT design, sample size
calculation for the primary endpoint was made under
the assumption that during the 5-year observational
period about 30% of the subjects in the intervention
group and 20% of the subjects in the control group will
develop hypertension. The detectable risk increase is
compatible with 80% power and the significance of 0.05
is 10%. Based on this assumption, a sample size of n = 289
was required for each group. For the NN, PN, and HN
groups, we adopted a minimum sample size, which is the
same as that for each RCT group. The targeted sample
size for the enrolment was estimated with the minimum
sample size for the five groups (n = 1445) multiplied by
1.2 with the consideration for the loss of participants dur-
ing the follow–up period. In total, the targeted sample size
was 1800.Table 2 Baseline characteristics of eligible study participants
Variables NN
n 8542
Age (x  s, yrs) 37.1 ± 11.4
Gender (Male %) 39.8
BMI (x  s, kg/m2) 22.8 ± 3.1
Waist circumstance (x  s, cm) 75.2 ± 13.2
Sbp (x  s, mm Hg) 106.7 ± 6.9
Dbp (x  s, mm Hg) 67.7 ± 5.7
Serum uric acid (x  s, mg/dl) 4.7 ± 1.0
Total cholesterol (x  s, mg/dL) 4.9 ± 0.9
Triglycerides (x  s, mg/dL) 1.1 ± 0.9
LDL (x  s, mg/dL) 3.1 ± 0.8
HDL (x  s, mg/dL) 1.4 ± 0.3
Fasting glucose (x  s, mg/dL) 4.7 ± 0.8
Diabetes (%) 1.8
*Normaltension and no-hyperuricemia (NN), Prehypertension and no-hyperuricemia
hyperuricemia (PH).Outcome and statistical analysis
The primary evaluation criterion for the present study is
the manifestation of hypertension. Cox proportional-
hazards regression was used to identify the association be-
tween baseline uric acid levels with the occurrence of
hypertension in the non-intervention cohort. We used
mixed models since we had correlated repeat observations
of uric acid, blood pressure, and lipid profile. We then,
compared the change in BMI, uric acid, and blood pres-
sure from the baseline to five years for each subgroup.
Baseline characteristics of the eligible subjects
Based on the results of their health examination in 2010,
19, 724 subjects met the inclusion criteria including
10, 423 males and 9, 301 females. The average age of the
participants was 40.1 ± 13.1 years (range, 14 to 92 years).
Baseline characteristics are presented in Table 2. The re-
quired minimum sample size was guaranteed. Individuals
aged from 35–75 years were asked if he or she would par-
ticipate in their scheduled annual health check-ups.
The prevalence of prehypertension and hyperuricemia
was 52.0% (n = 10,265) and 12.6% (n = 2495), respectively.
The prevalence of prehypertension was higher for male
(61.9%) than that for female (41.0%, chi-square = 854.0,
p < 0.001). The prevalence of hyperuricemia was higher
for male (16.9%) than that for female as well (7.9%, chi-
square = 365.5, p < 0.001). Overweight and obese subjects
had a high prevalence of prehypertension (65.0% and
78.6% in male; 55.5% and 70.6% in female). Subjects with
abdominal obesity were more likely to have high-normal
blood pressure than subjects without abdominal obesity
(56.5% vs. 75.4% in male and 37.8% vs. 69.2% in female).
Subjects with hyperuricemia had a higher prevalence than
subjects without hyperuricemia (60.8% and 67.2% in male;PN NH PH
8687 917 1578
42.7 ± 13.9 38.3 ± 12.0 42.7 ± 14.1
60.6 63.1 75.1
24.8 ± 3.4 24.5 ± 3 .3 26.5 ± 3.4
82.2 ± 10.4 81.5 ± 10.4 87.5 ± 9.9
124.3 ± 6.4 108.2 ± 6.4 124.7 ± 6.6
78.4 ± 5.7 68.9 ± 5.4 79.2 ± 5.5
5.0 ± 1.1 7.3 ± 0.8 7.5 ± 0.9
5.2 ± 1.0 5.3 ± 1.0 5.4 ± 1.0
1.5 ± 1.3 1.9 ± 1.4 2.2 ± 1.7
3.3 ± 0.9 3.4 ± 0.9 3.3 ± 0.9
1.4 ± 0.3 1.3 ± 0.3 1.3 ± 0.3
4.9 ± 1.1 4.9 ± 1.0 5.0 ± 0.9
4.1 3.2 4.0
(PN), normaltension and hyperuricemia (NH)and Prehypertension and
Table 4 Multiple logistic regression of variables
associated with prehypertension
Variables Male Female
OR 95% CI OR 95% CI
Age group
Young (18–34) 1 — 1 —
Middle (35–64) 1.00 0.91–1.09 1.93 1.76–2.12
Old (65-) 2.71 2.12–3.48 7.29 5.40–9.83
BMI
<18.5 0.55 0.40–0.76 0.68 0.55–0.83
18.5–23.9 1 — 1 —
24–27.9 1.72 1.57–1.89 2.02 1.82–2.25
28- 2.81 2.39–3.31 3.27 2.63–4.07
Abdominal obesity
No 1 — 1 —
Yes 1.43 1.26–1.61 1.26 1.04–1.53
Hyperuricemia
No 1 — 1 —
Yes Not significant 1.39 1.18–1.64
Song et al. BMC Public Health 2013, 13:1069 Page 4 of 7
http://www.biomedcentral.com/1471-2458/13/106940.0% and 53.8% in female) (Table 3). The association of
prehypertension with age was stronger for female than
male as the odds ratio was 1.01 (95% CI: 0.91–1.09), 2.71
(95% CI: 2.12–3.48) for middle and old age male groups
and 1.93 (95% CI: 1.76–2.12), and 7.29 (95% CI: 5.40–9.83)
for middle and old age female groups. Hyperuricemia was
significantly associated with prehypertension independent
of the age group, BMI, and abdominal obesity among
female subjects in a forward multiple logistic regression
analysis, however this was not the case among the male
subjects (Table 4).
Discussion
Despite evidences from a number of observational stud-
ies that demonstrate a relation between serum uric acid
levels and hypertension, whether treating asymptomatic
hyperuricemia contributes to the prevention of hyper-
tension is still controversial. A prospective cohort study
with a nested randomised controlled trial was designed
to test the hypothesis that lowering uric acid levels by
dietary intervention delivered by an educational package
might prevent or postpone the occurrence of hyperten-
sion. Our study is intended as an exploration for the
potential practical option of preventing hypertension
besides providing proof of the physiological mecha-
nisms involved.
In this prospective cohort study, four cohorts are be-
ing followed with the diagnosis of hypertension as the
endpoint for each of the participant. The first question
that will be answered is whether people with hyperurice-
mia are more likely to process from normal or high-
normal blood pressure to hypertension or not. RecentTable 3 The prevalence of prehypertension in subgroups reg
and Hyperuricemia
Variables Male
N n % χ2
Age group
Young (18–34) 4066 2405 59.1 78.9
Middle (35–64) 5897 3674 62.3
Old (65-) 460 369 80.2
BMI
<18.5 171 62 36.3 287.3
18.5–23.9 3528 1767 50.1
24–27.9 4776 3106 65.0
28- 1820 1431 78.6
Abdominal obesity
No 7379 4166 56.5 164.0
Yes 2919 2202 75.4
Hyperuricemia
No 8659 5263 60.8 24.4
Yes 1764 1185 67.2experimental and clinical evidence supports the pos-
sibility elevated uric acid levels leading to hyperten-
sion [5,8,11-14]. In another prospective nested case
control study, uric acid level was not associated with
an increased risk of incidence of hypertension among
older men and even in the subgroup of men who
were < 60 years of age, this significant association was
attenuated and no longer significant after further
controlling for fasting insulin, triglycerides, and total
cholesterol [11].arding to Age, BMI, Abdominal Circumference
Female
P N n % χ2 P
0.000 4361 1248 18.6 648.1 0.000
4613 2303 49.9
327 266 81.3




0.000 8268 3126 37.8 75.1 0.000
864 598 69.2
0.000 8570 3424 40.0 53.1 0.000
731 393 53.8
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fers protection against the development of hypertension
remains untested. Regardless of the pathophysiological
explanations, the observation that a high level of uric
acid was associated with hypertension implies that it is
possible to prevent or postpone the onset of hyperten-
sion by reducing serum uric acid. Randomised trial data
on the effect of the intervention of lowering uric acid on
the prevention or treatment of hypertension would be
valuable. The nested RCT aims to identify the efficacy of
a uric-acid lowering education package that is character-
ized as a purine-restriction lifestyle intervention. These
include decreasing the consumption of protein, purines,
and alcohol, as well as reducing obesity. Most uric acid
comes from endogenous sources, therefore, diet is con-
sidered as playing a minor role in the treatment of hyper-
uricemia. It is still controversial whether asymptomatic
hyperuricemia should be treated by lowering uric acid
medications [15]. Although the uric-acid lowering effect
appeared weaker than that of uric-acid lowering drugs,
other associated health benefits would make lifestyle
modifications important, particularly in the high risk
of hypertension population [16,17]. Lifestyle modifica-
tion intervention is considered as a practical strategy
for the treatment of asymptomatic hyperuricemia.
Healthy lifestyle interventions would form a basic
therapeutic approach not only for hyperuricemia but
also for hypertension,metabolic syndrome, and cardio-
vascular disease, though it is not easy to promote be-
havioural changes. It must be noted that a small reduction
in the relative risk of hypertension can translate into large
public health gains considering that more than 1.6 hun-
dred million people in China suffer from hypertension.
The outcomes of the RCT include controlling the occur-
rence rate of hyperuricemia and the transition rate to
hypertension. In addition, a comparison of the transition
rate to hypertension will be performed between the con-
trolled hyperuricemia group and the uncontrolled hyper-
uricemia group.
Nesting an RCT within a cohort study is less likely to
damage the overall observational nature of the study
[18]. On the contrary, the RCT is potentially beneficial
to the health of the participants and hence, it would in-
crease the interest and enthusiasm of the staff and par-
ticipants ensuring quality control during observations
and data collection. It is possible that the RCT interven-
tions would have altered the population cohort’s integ-
rity, but for most interventions, the bias should be no
different from that found in a normal observation study.
Statistical analysis of the intervention will be conducted,
where appropriate. A potential bias would be in the
uric-acid lowering treatment for patients with symptoms
of hyperuricemia. Subjects will be asked whether he or
she had uric-acid lowering treatment in the last year,and if so this will be considered as a covariate during
analysis.
There are several challenges to the implementation of
this study. First, subject loss during the follow-up period
is problematic in most cohort studies and it often leads
to bias. A simulation study identified that seriously
biased estimates of the odds ratios were obtained when
observations were lost during the follow-up based on
missing of random mechanisms [19]. The best way of
dealing with loss during follow-up is to avoid it. Some
efforts were made equally for each of group to avoid loss
during follow-up. The employee whose employer had a
long-term annual check-up contract with our centre was
given priority for enrolling in this study with the expect-
ation of the potential for a high compliance rate. At the
start of this study, the names of two or more family
members or friends who do not live with our partici-
pants were asked for enrolling in the study program.
Small gifts were given as financial compensation for the
time lost in completing the questionnaires for this study.
Full-time personnel were hired for this task. Second, se-
lection bias is built into the cohort studies. Participants
who have hyperuricemia at the baseline probably differ
in other important factors that are associated with the
risk of hypertension. The information on other known
risk factors of hypertension was collected for stratified
and multivariate analyses. Over time, the exposure status
(hyperuricemia) of the study participants can change.
Serum uric acid will be measured annually to identify
the potential change in its level. Third, non-adherence
to highly effective recommendations can lead to inter-
vention failure. Non-adherence rate is one of the out-
comes that will be evaluated. Participants will be asked
whether he/she has made a lifestyle change after the
intervention and the potential factors associated with
non-adherence will be identified. Factors associated with
non-adherence in this study will be investigated accord-
ing to the information filled in the questionnaire. Mea-
sures could be developed to ensure the implementation
of intervention. In addition, a potential bias would be in
the uric-acid lowering treatment for patients with symp-
toms of hyperuricemia. Subjects will be asked whether
he or she had uric-acid lowering treatment in the last
year, and if so it will be considered as a covariate during
analysis. Finally, as this is a single-centre study, with less
attention to details results may not be replicable in other
settings. With the consideration of the beneficial inter-
vention, one could apply the findings of this single-
centre study only after comparing the context of the trial
with his or her situation. The subjects in this study were
employed by an employer who had a long-term contract
with the Health Management Centre. One should be
cautious when generalizing the research results to other
populations.
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subjects screened in our centre. Hyperuricemia was as-
sociated with prehypertension, and was independent of
age, body mass index (BMI), and abdominal obesity in
females; however, in males it was contrary. The relation-
ship between gender difference and the association for
uric acid with blood pressure was in line with the finding
of a meta-analysis of 18 prospective studies on the asso-
ciation between hyperuricemia and hypertension [20].
Hormonal factors might influence uric acid level and they
potentially have an impact on the relationships between
uric acid and blood pressure [21-23]. Further investigation
of selected medical conditions, uric acid, and hormonal
factors in hypertension development is warranted.
Limitations of the current study include those inherent
to any study of common lifestyle factors for both hyper-
uricemia and hypertension. In all dietary studies focusing
on individual lifestyle factors, there is the potential for
confounding due to the fact that many lifestyle factors
are correlated. Information of potential confounding fac-
tors including sodium intake were collected as much as
we can and multivariate statistical analysis will be
adopted by considering multiple risk factors. Another
potential limitation would be the size of the cohorts. As
noted previously, there are many potential confounding
factors should be taken into account to draw meaning
conclusion. The current estimated sample size might at-
tenuate the power of this study. The sample size would be
re-calculated after preliminary results were obtained from
the cohorts and a sequential design was considered.
Although there are a number of observational studies
that report a on the relation between serum uric acid
levels and hypertension, the impact of lowering uric acid
on the prevention of hypertension is still inconclusive
and requires further investigation. This RCT in the co-
hort study will provide important data on a group of
subjects who are at a high risk of developing hyperten-
sion. A clear guideline regarding the choice of treatment
of asymptomatic hyperuricemia is unavailable and this
study aims to provide that.
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